Lokivetmab

Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.^[1] It acts against interleukin 31 (IL-31),^[2] which is a cytokine involved in causing itchiness (pruritus).^[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.^[3]

Lokivetmab

Monoclonal antibody
Type	Whole antibody
Target	interleukin 31 (IL-31)
Clinical data
Trade names	Cytopoint
Routes of administration	subcutaneous injection
ATCvet code	QD11AH91 (WHO)
Legal status
Legal status	veterinary use
Identifiers
CAS Number	1533403-95-0 Y
UNII	3D6091GOHH

The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,^[3] and it was approved by the European Medicines Agency in 2017.^[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.^[4]